Baidu
map

Circulation:桡动脉血管作为补充移植物可降低不良心血管事件的发生风险!

2017-06-01 MedSci MedSci原创

桡动脉(RA)血管是否可以改善冠状动脉旁路移植(CABG)手术的临床疗效? 近日在circulation上发表的一篇文章针对该点展开研究。该研究建立了动态血运重建试验(ART),这项试验旨在评估双侧内胸动脉(BITA)在单个左内胸动脉(SITA)上的存活率情况。

桡动脉(RA)血管是否可以改善冠状动脉旁路移植(CABG)手术的临床疗效? 近日在Circulation上发表的一篇文章针对该点展开研究。该研究建立了动态血运重建试验(ART),这项试验旨在评估RA作为双侧胸廓内动脉(BITA)或者单个左胸廓内动脉(SITA)替代血管的患者存活率。

在ART中,大部分患者(约20%)接受了RA移植取代隐静脉移植物(SVG)。研究人员旨在调查使用RA(不是SVG)提供SITA或BITA移植补充物后对其疗效的关联性,并通过对ART的事后分析得出研究结果。

在试验进行过程中,研究人员对参加ART(n = 3102)的患者根据实际接受的血管类型进行分类。将接受SITA或BITA移植的患者主要分为两组:接受RA移植(RA组,n = 632)以及接受SVG移植(SVG组,n = 2105)的2737名患者。试验主要观测指标为5年心肌梗死心血管死亡和重复血运重建的复合报告情况。在记录数据后,使用倾向得分匹配和分层Cox回归来评估两种方案。

最终结果显示,两组的MI、心血管死亡和重复血运重建累积发生率分别为:RA组为2.3%(95%CI 1.1-3.4),3.5%(95%CI 2.1-5.0)和4.4%(95%CI 2.8-6.0) SVG组的3.4%(95%CI 2.0-4.8),4.0%(95%CI 2.5-5.6)和7.6%(95%CI 5.5-9.7)。除此之外,对于三项不良结果的复合报告情况为:SVG组(13.6%; 95%CI 10.8-16.3),RA组(8.8%; 95%CI 6.5-11.0)(P = 0.005),RA组显着降低。该数据反映出当RA移植物用于补充SITA和BITA移植物时,对原有方案的疗效有影响(相互作用P = 0.62)。

这项后期ART分析显示,当RA用于补充SITA或BITA移植物时,可降低中期主要不良心脏事件的风险。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1745238, encodeId=de2e1e452383d, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Tue Apr 17 21:53:00 CST 2018, time=2018-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643460, encodeId=ea0a16434602e, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Mon Nov 06 22:53:00 CST 2017, time=2017-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708968, encodeId=09a31e0896899, content=<a href='/topic/show?id=1502333250f' target=_blank style='color:#2F92EE;'>#动脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33325, encryptionId=1502333250f, topicName=动脉血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048f31575940, createdName=ms9833124466084992, createdTime=Thu Jan 11 05:53:00 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441095, encodeId=e1121441095cb, content=<a href='/topic/show?id=81a3623569c' target=_blank style='color:#2F92EE;'>#桡动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62356, encryptionId=81a3623569c, topicName=桡动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae384789560, createdName=12498aa2m63(暂无昵称), createdTime=Sat Jun 03 14:53:00 CST 2017, time=2017-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620693, encodeId=c2b516206932f, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Sat Jun 03 14:53:00 CST 2017, time=2017-06-03, status=1, ipAttribution=)]
    2018-04-17 xuyong535
  2. [GetPortalCommentsPageByObjectIdResponse(id=1745238, encodeId=de2e1e452383d, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Tue Apr 17 21:53:00 CST 2018, time=2018-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643460, encodeId=ea0a16434602e, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Mon Nov 06 22:53:00 CST 2017, time=2017-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708968, encodeId=09a31e0896899, content=<a href='/topic/show?id=1502333250f' target=_blank style='color:#2F92EE;'>#动脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33325, encryptionId=1502333250f, topicName=动脉血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048f31575940, createdName=ms9833124466084992, createdTime=Thu Jan 11 05:53:00 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441095, encodeId=e1121441095cb, content=<a href='/topic/show?id=81a3623569c' target=_blank style='color:#2F92EE;'>#桡动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62356, encryptionId=81a3623569c, topicName=桡动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae384789560, createdName=12498aa2m63(暂无昵称), createdTime=Sat Jun 03 14:53:00 CST 2017, time=2017-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620693, encodeId=c2b516206932f, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Sat Jun 03 14:53:00 CST 2017, time=2017-06-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1745238, encodeId=de2e1e452383d, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Tue Apr 17 21:53:00 CST 2018, time=2018-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643460, encodeId=ea0a16434602e, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Mon Nov 06 22:53:00 CST 2017, time=2017-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708968, encodeId=09a31e0896899, content=<a href='/topic/show?id=1502333250f' target=_blank style='color:#2F92EE;'>#动脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33325, encryptionId=1502333250f, topicName=动脉血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048f31575940, createdName=ms9833124466084992, createdTime=Thu Jan 11 05:53:00 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441095, encodeId=e1121441095cb, content=<a href='/topic/show?id=81a3623569c' target=_blank style='color:#2F92EE;'>#桡动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62356, encryptionId=81a3623569c, topicName=桡动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae384789560, createdName=12498aa2m63(暂无昵称), createdTime=Sat Jun 03 14:53:00 CST 2017, time=2017-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620693, encodeId=c2b516206932f, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Sat Jun 03 14:53:00 CST 2017, time=2017-06-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1745238, encodeId=de2e1e452383d, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Tue Apr 17 21:53:00 CST 2018, time=2018-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643460, encodeId=ea0a16434602e, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Mon Nov 06 22:53:00 CST 2017, time=2017-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708968, encodeId=09a31e0896899, content=<a href='/topic/show?id=1502333250f' target=_blank style='color:#2F92EE;'>#动脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33325, encryptionId=1502333250f, topicName=动脉血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048f31575940, createdName=ms9833124466084992, createdTime=Thu Jan 11 05:53:00 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441095, encodeId=e1121441095cb, content=<a href='/topic/show?id=81a3623569c' target=_blank style='color:#2F92EE;'>#桡动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62356, encryptionId=81a3623569c, topicName=桡动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae384789560, createdName=12498aa2m63(暂无昵称), createdTime=Sat Jun 03 14:53:00 CST 2017, time=2017-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620693, encodeId=c2b516206932f, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Sat Jun 03 14:53:00 CST 2017, time=2017-06-03, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1745238, encodeId=de2e1e452383d, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Tue Apr 17 21:53:00 CST 2018, time=2018-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643460, encodeId=ea0a16434602e, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Mon Nov 06 22:53:00 CST 2017, time=2017-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708968, encodeId=09a31e0896899, content=<a href='/topic/show?id=1502333250f' target=_blank style='color:#2F92EE;'>#动脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33325, encryptionId=1502333250f, topicName=动脉血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048f31575940, createdName=ms9833124466084992, createdTime=Thu Jan 11 05:53:00 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441095, encodeId=e1121441095cb, content=<a href='/topic/show?id=81a3623569c' target=_blank style='color:#2F92EE;'>#桡动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62356, encryptionId=81a3623569c, topicName=桡动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae384789560, createdName=12498aa2m63(暂无昵称), createdTime=Sat Jun 03 14:53:00 CST 2017, time=2017-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620693, encodeId=c2b516206932f, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Sat Jun 03 14:53:00 CST 2017, time=2017-06-03, status=1, ipAttribution=)]

相关资讯

J Rheumatol:研究没有发现RA和CAD的遗传相关性

根据遗传分析的结果,没有证据表明,类风湿关节炎相关的单核苷酸多态性与冠状动脉疾病有关。“如果类风湿关节炎(RA)与冠状动脉疾病(CAD)存在因果关系,那么RA相关的基因就可以看做可预测冠心病风险增加的因素。”来自德国慕尼黑理工大学的Henning Jansen博士说:“然而,在我们的大数据集,包括22233例CAD和64762例对照组,没有发现支持联系的证据。”为了评估RA和CAD是否存在共同病因

Arthritis Rheumatol:全球类风湿性关节炎作为死亡原因的变化趋势!

由此可见,归因于RA的死亡率在全球范围内有所下降。然而,RA死亡率上存在着很大的国家之间的差距,但随着时间的推移国家间差距有所减少。人口老龄化以及RA死亡率的下降可能会导致疾病的经济负担增加,这个问题在制订政策时应予以考虑。

Semin Arthritis Rheum:RA患者结核感染后可否继续使用生物制剂

肿瘤坏死因子拮抗剂(TNFi)目前用于治疗许多慢性炎症性疾病,包括类风湿关节炎(RA),强直性脊柱炎,银屑病关节炎等。TNFi 对细胞内细菌感染(如结核杆菌)的免疫应答起着关键作用。已有研究显示,接受 TNFi 治疗的风湿病患者结核感染风险增加 0.6 至 24.1 倍。 对于已有结核感染的 RA 患者是否能继续使用 TNFi 这个问题,韩国学者 Cho 等给出了答案,结果发表在近期的杂志 Sem

类风湿新药进展!强生向美国FDA提交IL-6单抗sirukumab上市申请

美国医药巨头强生(JNJ)旗下杨森生物科技(Jassen Biotech)近日宣布已向美国食品和药物管理局(FDA)提交皮下注射剂型(SC)单抗药物sirukumab(皮下注射,每月一次)的生物制品许可申请(BLA),寻求批准sirukumab用于对一种或多种疾病修饰抗风湿药物(DMARDs)治疗失败或不耐受的中度至重度类风湿性关节炎(RA)成人患者。 sirukumab是一种实验性人抗细胞白介

Eur Heart J:银屑病关节炎、银屑病和类风湿关节炎患者静脉血栓栓塞的风险如何?

由此可见,虽然全身炎症是VTE的危险因素,与对照者相比,发生VTE的风险在三种不同的炎症性疾病:类风湿关节炎、PsA和牛皮癣的患者中是不同的。

Arthritis Rheumatol:特立帕肽对类风湿性关节炎患者关节侵蚀的疗效如何?

由此可见,采用特立帕肽治疗一年并没有显著减少采用TNFi治疗控制疾病活动的RA患者手部或手腕的侵蚀体积。

Baidu
map
Baidu
map
Baidu
map